• CF102 CHEMBL431733 Antineoplastic

    Alternate Names:

    CF-102
    CI-IB-MECA
    Chloro-IB-MECA
    BETA-D-RIBOFURANURONAMIDE, 1-(2-CHLORO-6-(((3-IODOPHENYL)METHYL)AMINO)-9H-PURIN-9-YL)-1-DEOXY-N-METHYL-
    1-[2-CHLORO-6-[[(3-IODOPHENYL)METHYL]AMINO]-9H-PURIN-9-YL]-1-DEOXY-N-METHYL-?-D-RIBOFURANURONAMIDE
    (2S,3S,4R,5R)-5-[2-CHLORO-6-[(3-IODOPHENYL)METHYLAMINO]PURIN-9-YL]-3,4-DIHYDROXY-N-METHYL-TETRAHYDROFURAN-2-CARBOXAMIDE
    (2S,3S,4R,5R)-5-(6-(3-IODOBENZYLAMINO)-2-CHLORO-9H-PURIN-9-YL)-3,4-DIHYDROXY-N-METHYL-TETRAHYDROFURAN-2-CARBOXAMIDE
    2-CHLORO-N6-(3-IODOBENZYL)-ADENOSINE-5 INVERTED EXCLAMATION MARKA-N-METHYLURONAMIDE
    2-CHLORO-N6-(3-IODOBENZYL)ADENOSINE-5-N-METHYLCARBOXAMIDE
    3B3-072369
    ST24034136
    KB-276752
    AB0047892
    SMR001230862
    NU006997
    NU000919
    AN-17022
    AK-60479
    NCGC00025001-02
    2-CHLORO-N(6)-(3-IODOBENZYL)-9-(5-(METHYLCARBAMOYL)-BETA-D-RIBOFURANOSYL)ADENINE
    AM84557
    AKOS022181265
    DNC000447
    CF 102
    ZINC3995845
    HMS2235L10
    2-CHLORO-N6-(3-IODOBENZYL)ADENOSINE-5'-N-METHYLCARBOXAMIDE
    2-CHLORO-N(6)-(3-IODOBENZYL)ADENOSINE-5'-N-METHYLURONAMIDE
    BDBM21221
    Z07JR07J6C
    SCHEMBL1170028
    MLS002153535
    GTPL457
    UNII-Z07JR07J6C
    C1-IB-MECA
    1-(2-CHLORO-6-(((3-IODOPHENYL)METHYL)AMINO)-9H-PURIN-9-YL)-1-DEOXY-N-METHYL-BETA-D-RIBOFURANURONAMIDE
    1-[2-CHLORO-6-[[(3-IODOPHENYL)METHYL]AMINO]-9H-PURIN-9-YL]-1-DEOXY-N-METHYL-BETA-D-RIBOFURANURONAMIDE
    (2S,3S,4R,5R)-5-(2-CHLORO-6-{[(3-IODOPHENYL)METHYL]AMINO}-9H-PURIN-9-YL)-3,4-DIHYDROXY-N-METHYLOXOLANE-2-CARBOXAMIDE
    (2S,3S,4R,5R)-5-[2-CHLORO-6-[(3-IODOPHENYL)METHYLAMINO]PURIN-9-YL]-3,4-DIHYDROXY-N-METHYLOXOLANE-2-CARBOXAMIDE
    (2S,3S,4R,5R)-5-(2-CHLORO-6-((3-IODOBENZYL)AMINO)-9H-PURIN-9-YL)-3,4-DIHYDROXY-N-METHYLTETRAHYDROFURAN-2-CARBOXAMIDE
    2CL-IB-MECA
    C-IBZA-MU
    163042-96-4
    2-CL-IB-MECA
    3035850
    CL-IB-MECA
    C277_SIGMA
    AC1MI03J
    DCL001171
    135650107
    457

    Drug Info:

    FDA Approval not approved
    Drug Class Small molecule
    Drug Indications antineoplastic agent
    (1 More Sources)

    Publications:

  • Interaction Types:
    agonist

    Interaction Info:
    Mechanism of Interaction Adenosine A3 receptor agonist
    Direct Interaction yes
    Specific Action of the Ligand Full agonist

    Publications:

  • Interaction Types:
    agonist

    Interaction Info:
    Specific Action of the Ligand Agonist
    Endogenous Drug? False

    Publications:

  • Interaction Types:
    agonist

    Interaction Info:
    Specific Action of the Ligand Agonist
    Endogenous Drug? False

    Publications:

  • Interaction Types:
    agonist

    Interaction Info:
    Specific Action of the Ligand Agonist
    Endogenous Drug? False

    Publications:

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antineoplastic agent
    Drug Class Small molecule
    FDA Approval not approved

    Publications:

    • Version: 09-Feb-2016

    Alternate Names:
    AC1MI03J Drug Synonym
    C277_SIGMA Drug Synonym
    CL-IB-MECA pubchem_primary_name

    Drug Info:

    Publications:

    • Version: 4.3.02 (25-August-2011)

    Alternate Names:
    DCL001171 TTD Drug Id
    CF102 Primary Drug Name

    Drug Info:

    Publications:

    • Version: 27-September-2017

    Alternate Names:
    CL-IB-MECA GuideToPharmacology Ligand Name
    135650107 PubChem Drug SID

    Drug Info:

    Publications:

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications: